Nautilus Biotechnology, Inc. (NAUT)
Market Cap | 301.35M |
Revenue (ttm) | n/a |
Net Income (ttm) | -70.21M |
Shares Out | 125.56M |
EPS (ttm) | -0.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 89,686 |
Open | 2.400 |
Previous Close | 2.380 |
Day's Range | 2.380 - 2.500 |
52-Week Range | 2.190 - 3.455 |
Beta | 1.04 |
Analysts | Buy |
Price Target | 4.50 (+87.5%) |
Earnings Date | Oct 29, 2024 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affin... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for NAUT stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 87.50% from the latest price.
News
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mal...
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executiv...
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder & Chief Executive Off...
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founde...
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resu...
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report...
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics Society award recognizes Dr. Mallick's decades of innovative leaders...
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder...
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Fou...
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial resul...
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology to Participate in Upcoming August Investor Conferences
SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company wil...
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executi...
Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financia...
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will...
Nautilus Biotechnology Reports First Quarter 2023 Financial Results
SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial result...
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report...